GlassScriptPhysician profile
Rock Vomer
NPI 1740740448
$1,050.09
in general payments reported to CMS, 2019-2025
18 companies · $565 in 2025
The $565 reported for 2025 was more than what 84% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.24 · 2022: $15.72 · 2023: $14.80 · 2024: $443 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.54 | 2024-2025 | |
| Exact Sciences Corporation | $120.35 | 2024-2025 | Cologuard Collection Kit |
| Baxter Healthcare | $115.73 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $78.46 | 2024-2025 | Airsupra |
| Novo Nordisk INC | $78.24 | 2022-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $49.74 | 2025 | Rexulti |
| Organon LLC | $48.81 | 2024 | |
| Inspire Medical Systems, INC. | $46.35 | 2025 | Inspire |
| Lilly USA, LLC | $46.30 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $33.85 | 2024-2025 | Auvelity |
| Radius Health, INC. | $28.86 | 2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.06 | 2024 | Jardiance |
| Abbott Laboratories | $22.09 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $19.71 | 2025 | Veozah |
| Irhythm Technologies, INC. | $17.01 | 2024 | Zio Xt Patch, Zio Monitor |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.80 | 2023 | Shingrix |
| Amgen INC. | $13.95 | 2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rock Vomer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.